Ferguson Wellman Capital Management Inc. reduced its holdings in shares of Celgene Corporation (NASDAQ:CELG) by 6.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,112 shares of the biopharmaceutical company’s stock after selling 326 shares during the quarter. Ferguson Wellman Capital Management Inc.’s holdings in Celgene Corporation were worth $664,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in CELG. Hudson Valley Investment Advisors Inc. ADV grew its stake in Celgene Corporation by 17.2% during the first quarter. Hudson Valley Investment Advisors Inc. ADV now owns 20,676 shares of the biopharmaceutical company’s stock worth $2,573,000 after buying an additional 3,030 shares during the period. Diversified Trust Co grew its stake in Celgene Corporation by 0.4% during the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 9 shares during the period. Westwood Management Corp IL grew its stake in Celgene Corporation by 102.0% during the first quarter. Westwood Management Corp IL now owns 213,330 shares of the biopharmaceutical company’s stock worth $26,545,000 after buying an additional 107,700 shares during the period. V Wealth Management LLC purchased a new stake in Celgene Corporation during the first quarter worth approximately $1,252,000. Finally, Northern Capital Management LLC grew its stake in Celgene Corporation by 7.4% during the first quarter. Northern Capital Management LLC now owns 7,145 shares of the biopharmaceutical company’s stock worth $889,000 after buying an additional 490 shares during the period. Institutional investors own 79.43% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2887745/ferguson-wellman-capital-management-inc-decreases-holdings-in-celgene-corporation-celg.html.
Celgene Corporation (NASDAQ:CELG) opened at 142.07 on Wednesday. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $142.64. The company has a market cap of $111.15 billion, a price-to-earnings ratio of 44.00 and a beta of 1.89. The stock’s 50 day moving average is $134.40 and its 200 day moving average is $126.94.
Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s revenue was up 18.7% on a year-over-year basis. During the same period last year, the business earned $1.44 earnings per share. On average, analysts predict that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.
Several research firms have issued reports on CELG. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $175.00 price objective (up from $148.00) on shares of Celgene Corporation in a research note on Monday, July 31st. Cantor Fitzgerald set a $160.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Thursday, July 27th. BMO Capital Markets reiterated an “outperform” rating and set a $160.00 price objective (up from $152.00) on shares of Celgene Corporation in a research note on Friday, July 28th. Canaccord Genuity set a $156.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Tuesday, June 6th. Finally, BidaskClub upgraded shares of Celgene Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twenty-two have issued a buy rating to the stock. Celgene Corporation has an average rating of “Buy” and a consensus target price of $147.31.
In other Celgene Corporation news, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the transaction, the insider now directly owns 4,004 shares of the company’s stock, valued at $481,200.72. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael D. Casey sold 9,250 shares of Celgene Corporation stock in a transaction on Monday, June 19th. The shares were sold at an average price of $125.59, for a total value of $1,161,707.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 263,011 shares of company stock valued at $35,078,473. Company insiders own 0.95% of the company’s stock.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.